Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy

BJU International

Volumn 94, Issue 9, 2004, Pages 1235-1238

  Joseph, Joji ^a   Al Qaisieh, Bashar ^a   Ash, Daniel ^a   Bottomley, David ^a   Carey, Brendan ^a  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

125Iodine; Brachytherapy; Gleason score; Outcome; Prostate cancer; PSA

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CYTOREDUCTIVE SURGERY; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIVARIATE ANALYSIS OF COVARIANCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 11144223896     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05149.x     Document Type: Article

References (16)

1. Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I. Transperineal Iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130: 183-6
2. Beyer DC, Priestley JB. Biochemical and disease free survival following iodine 125 prostate implantation. Int J Radiat Oncol Biol Phys 1997; 37: 559-63
3. Grado GL, Larson TR, Balch CS et al. Actuarial disease free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998; 42: 289-96
4. Ragde H, Elgamal AA, Snow PB. Ten year disease free survival after transperineal sonography guided Iodine 125 brachytherapy with or without 45 Gy external beam irradiation in the treatment of patients with clinically localised low to high grade Gleason prostate carcinoma. Cancer 1998; 83: 898-1001
5. Blank LE, Gonzales-Gonzales D, DeReijke TM, Dabhoiwala MF, Koedooder K. Brachytherapy with transperineal iodine 125 seeds for local prostate cancer. Radiother Oncol 2000; 57: 307-13
6. Batterman JJ. Iodine 125 seed implantation for localised prostate cancer. J Brachyther Int 1998; 14: 21-7
7. Grimm PD, Blasko JC, Ragde H. Ultrasound guided transperineal implantation of iodine 125 and palladium 103 for the treatment of early stage prostate cancer. Technique concepts in planning, operative technique and evaluation. Urol Clin N Am 1994; 2: 113-25
8. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus Statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-941
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol 1958; 53: 457-9
10. Cox DR, Abadir R. Regression models and life tables. J Roy Statist Soc 1972; 34: 187-220
11. Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner K. Five year biochemical outcome and toxicity with transperineal CT planned permanent Iodine 125 prostate implantation for patients with localised prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261-6
12. Bolla M, Collette L, Blank L et al. Long term results with immediate androgen suppression and external radiation in patients with locally advanced prostate cancer. (An EORTC Study): a Phase III randomised trial. Lancet 2002; 360: 103-6
13. Martinez A, Galalae R, Gonzalez J et al. No apparent benefit at five years from a course of neoadjuvant concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol 2003; 170: 2296-301
14. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000; 6: 1187-92
15. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for iodine 125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41: 101-8
16. Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999; 5: 301-6